National Cancer Institute; Notice of Meeting, 8944 [2017-02156]

Download as PDF 8944 Federal Register / Vol. 82, No. 20 / Wednesday, February 1, 2017 / Notices Contact Person: Darryl C. Zeldin, Scientific Director & Principal Investigator, Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, 111 T.W. Alexander Drive, Mail drop A2–09, Research Triangle Park, NC 27709, 919–541– 1169, zeldin@niehs.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS) Dated: January 26, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–02155 Filed 1–31–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting sradovich on DSK3GMQ082PROD with NOTICES Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the meeting of the President’s Cancer Panel. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: President’s Cancer Panel, ‘‘Pricing and Payment Strategies for Cancer Drugs: Maximizing Patients’ Access to Beneficial Therapies’’. Date: March 27, 2017. Time: 8:30 a.m. to 4:00 p.m. Agenda: Welcome and Introductions; Opening Presentations; The Pricing Landscape; Public Comment; Potential Actions To Encourage Pricing Strategies That Maximize Patients’ Access to Drug Therapy; The Payment Landscape; Wrap-Up and Final Remarks for the Day; Public Comment. Place: Kimpton Hotel Palomar, 117 South 17th Street, Philadelphia, PA 19103. Date: March 28, 2017. Time: 9:00 a.m. to 1:00 p.m. VerDate Sep<11>2014 16:23 Jan 31, 2017 Jkt 241001 Agenda: Welcome and Introductions; Day 1 Recap and Continuing Discussion on The Payment Landscape; Potential Actions To Encourage Payment Strategies That Maximize Patients’ Access to Drug Therapy; Conclusions and Cross-Cutting Recommendations; Wrap-Up and Next Steps; Public Comment. Place: Kimpton Hotel Palomar, 117 South 17th Street, Philadelphia, PA 19103. Contact Person: Abby B. Sandler, Ph.D., Executive Secretary, President’s Cancer Panel, Special Assistant to the Director, Rare Tumors Initiative, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Building 31, Room B2B37, MSC 2590, Bethesda, MD 20892– 8349, 301–451–9399, sandlera@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// prescancerpanel.cancer.gov/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: January 26, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel National Toxicology Program (NTP) Studies to Evaluate Test Agents. Date: February 16, 2017. Time: 8:30 a.m. to 4:30 p.m. Agenda: To review and evaluate contract proposals. Place: Sheraton Imperial Hotel & Convention Center 4700 Emperor Blvd., Durham, NC 27703. Contact Person: RoseAnne M. McGee, Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–30 Research Triangle Park, NC 27709, (919) 541– 0752, mcgee1@niehs.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS) Dated: January 25, 2017. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–02159 Filed 1–31–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2017–02156 Filed 1–31–17; 8:45 am] National Institutes of Health BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Auditory Neuroscience. Date: February 23–24, 2017. Time: 8:00 a.m. to 6:00 p.m. E:\FR\FM\01FEN1.SGM 01FEN1

Agencies

[Federal Register Volume 82, Number 20 (Wednesday, February 1, 2017)]
[Notices]
[Page 8944]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02156]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the meeting of the 
President's Cancer Panel.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: President's Cancer Panel, ``Pricing and 
Payment Strategies for Cancer Drugs: Maximizing Patients' Access to 
Beneficial Therapies''.
    Date: March 27, 2017.
    Time: 8:30 a.m. to 4:00 p.m.
    Agenda: Welcome and Introductions; Opening Presentations; The 
Pricing Landscape; Public Comment; Potential Actions To Encourage 
Pricing Strategies That Maximize Patients' Access to Drug Therapy; 
The Payment Landscape; Wrap-Up and Final Remarks for the Day; Public 
Comment.
    Place: Kimpton Hotel Palomar, 117 South 17th Street, 
Philadelphia, PA 19103.
    Date: March 28, 2017.
    Time: 9:00 a.m. to 1:00 p.m.
    Agenda: Welcome and Introductions; Day 1 Recap and Continuing 
Discussion on The Payment Landscape; Potential Actions To Encourage 
Payment Strategies That Maximize Patients' Access to Drug Therapy; 
Conclusions and Cross-Cutting Recommendations; Wrap-Up and Next 
Steps; Public Comment.
    Place: Kimpton Hotel Palomar, 117 South 17th Street, 
Philadelphia, PA 19103.
    Contact Person: Abby B. Sandler, Ph.D., Executive Secretary, 
President's Cancer Panel, Special Assistant to the Director, Rare 
Tumors Initiative, Center for Cancer Research, National Cancer 
Institute, NIH, 9000 Rockville Pike, Building 31, Room B2B37, MSC 
2590, Bethesda, MD 20892-8349, 301-451-9399, sandlera@mail.nih.gov.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: https://prescancerpanel.cancer.gov/, where an agenda and any 
additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: January 26, 2017.
Melanie J. Pantoja,
 Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-02156 Filed 1-31-17; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.